Friday, May 29, 2020

Chinese Upstart Ascletis Bags $100 Million in Series B Financing

Chinese biotech company Ascletis, which focuses on treatments of liver disease, scored $100 million in a Series B financing round. The company said it intends to use the proceeds to advance its pipeline as well as its sales force.

Testing Post

We are pleased to announce the opening of our new commercial-scale cGMP biologics perfusion manufacturing facility in the city of Wuxi, China. The $150 million commercial biologics manufacturing facility accommodates two 1000L...

SUBSCRIBE TO OUR NEWSLETTER

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WuXi NEWS